Ignite Creation Date:
2024-05-06 @ 1:06 AM
Last Modification Date:
2024-10-26 @ 10:59 AM
Study NCT ID:
NCT01726738
Status:
COMPLETED
Last Update Posted:
2020-11-23
First Post:
2012-11-08
Brief Title:
LCCC 1128 Open Label Phase II Trial of the BRAF Inhibitor Dabrafenib and the MEK Inhibitor Trametinib in Unresectable Stage III and Stage IV BRAF Mutant Melanoma Correlation of Resistance With the Kinome and Functional Mutations
Sponsor:
Organization:
UNC Lineberger Comprehensive Cancer Center
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
17
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: